Table 2.
Therapeutic modulation of MCs in stroke models.
| Drugs | Experimental Model | Findings | References |
|---|---|---|---|
| PEA | MCAO rat model | PEA reduced MCs derived chymase and tryptase | [137] |
| Luteolin | OGD mouse MCs and neurons | Luteolin reduced OGD-activated MCs degranulation and induced neurotoxicity | [83] |
| PEA/Luteolin | OGD mouse MCs and neurons | PEA/Luteolin reduced OGD-activated MCs degranulation and MCs-induced neurotoxicity | [83] |
| MCAO rat model | PEA/Luteolin reduced ischemia-induced MCs infiltration and expression of chymase and tryptase | [148] | |
| Cromoglycate | Carotid ligation rat model | Cromoglycate reduced MCs migration, glial activation and brain atrophy | [71,72] |
| Ibotenate mouse model | Cromoglycate reduced MCs migration, glial activation and brain atrophy | [74] | |
| MCAO rat model | Cromoglycate reduced brain swelling, perivascular gelatinase activity, BBB leakage and neutrophil accumulation | [53,98] | |
| MCAO mouse model | Cromoglycate decreased BBB leakage, brain edema and neutrophils infiltration | [90] | |
| MCAO rat model treated with rtPA | Cromoglycate reduced rtPA-induced hemorrhagic conversion, brain swelling and neutrophil infiltration. | [98] | |
| Blood infusion rat model | Cromoglycate inhibited hematoma growth, decreased neurological deficits and mortality | [106] | |
| Collagenase infusion rat model treated with rtPA | Cromoglycate reduced rtPA-induced hematoma growth, hemispheric expansion, mortality and neurologic deficits. | [109] | |
| IVIG | Collagenase infusion mouse model | IVIG attenuated BBB damage, brain edema, infarct area and pro-inflammatory cytokines levels | [108] |
| H2 | Collagenase infusion mouse model | H2 decreased MCs accumulation and degranulation, BBB damage and improved neurobehavioral function | [107] |
| Carnosine | OGD rat MCs | Carnosine reduced degranulation and histamine release in OGD-activated MCs | [85] |
| Emedastine | CA rat model | Emedastine decreased MCs activation, inflammation and CA size and thinning. | [119] |
| Tranilast | CA rat model | Tranilast decreased MCs activation, inflammation and CA size and thinning. | [119] |
| MSCs | CA mouse model | Intravenous injection of MSCs reduced aneurysm rupture rate and CA MCs infiltration | [175] |
Studies showing MCs modulation by masitinib, scopoletin, resveratrol, polydatin and ketotifen in stroke models were not available at the moment of the manuscript submission. BBB: blood brain barrier; CA: cerebral aneurysm; ICH: intracerebral hemorrhage; MCAO: middle cerebral artery occlusion; MCs: mast cells; MSCs: mesenchymal stem cells; NHIBI: neonatal hypoxic-ischemic brain injury; OGD: oxygen and glucose deprivation; rtPA: recombinant tissue plasminogen activator; SAH: subarachnoid hemorrhage.